PE20121512A1 - Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa - Google Patents

Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa

Info

Publication number
PE20121512A1
PE20121512A1 PE2012000992A PE2012000992A PE20121512A1 PE 20121512 A1 PE20121512 A1 PE 20121512A1 PE 2012000992 A PE2012000992 A PE 2012000992A PE 2012000992 A PE2012000992 A PE 2012000992A PE 20121512 A1 PE20121512 A1 PE 20121512A1
Authority
PE
Peru
Prior art keywords
alkyl
gamma secretase
modulators
novelty
triazole derivatives
Prior art date
Application number
PE2012000992A
Other languages
English (en)
Inventor
Brandt Sven Franciscus Anna Van
Cleyn Michel Anna Jozef De
Henricus Jabobus Maria Gijsen
Didier Jean-Claude Berthelot
Michel Surkyn
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43569255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of PE20121512A1 publication Critical patent/PE20121512A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: HET1 ES UN HETEROCICLO DE FORMULA (a-1), (a-2), ENTRE OTROS; A1 ES CR9 O N; A2, A3 Y A4 SON INDEPENDIENTEMENTE CH O N SIEMPRE QUE MAXIMO DOS DE ELLOS SEAN N; L1 ES O, CARBONILO, NH(C=O), ENTRE OTROS; R1 ES CICLOALQUILO C3-7, ALQUENILO C2-6 O ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; L2 ES UN ENLACE DIRECTO, CARBONILO, O, S, ENTRE OTROS; R2 ES MORFOLINILO, PIPERIDINILO, PIPERAZINILO, ENTRE OTROS; R9 ES H, HALO O ALQUILOXI C1-4; R3 ES ALQUILO C1-4; R4, R5, Y R6 SON INDEPENDIENTEMENTE H, O ALQUILO C1-4; Xa ES CH O N; Xb ES O O S. SON COMPUESTOS PREFERIDOS: 5-(2-CLOROFENOXI)-N-[3-METOXI-4-(4-METIL-1H-IMIDAZOL-1-IL)FENIL]-1-(1-METILETIL)-1H-1,2,4-TRIAZOL-3-AMINA; N-[3-METOXI-4-(2-METIL-4-PIRIDINIL)FENIL]-1-(1-METILETIL)-5-[3-(TRIFLUORMETIL)-1-PIPERIDINIL]-1H-1,2,4-TRIAZOL-3-AMINA.2.2HCL.2.7H2O; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO ES MODULADOR DE LA ENZIMA GAMMA SECRETASA UTIL PARA EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, LESION CEREBRAL TRAUMATICA
PE2012000992A 2010-01-15 2011-01-12 Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa PE20121512A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10150892 2010-01-15
EP10171292 2010-07-29

Publications (1)

Publication Number Publication Date
PE20121512A1 true PE20121512A1 (es) 2012-12-06

Family

ID=43569255

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000992A PE20121512A1 (es) 2010-01-15 2011-01-12 Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa
PE2012000991A PE20121511A1 (es) 2010-01-15 2011-01-12 Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000991A PE20121511A1 (es) 2010-01-15 2011-01-12 Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa

Country Status (21)

Country Link
US (2) US9079886B2 (es)
EP (2) EP2523955B1 (es)
JP (2) JP5824464B2 (es)
KR (2) KR20120123677A (es)
CN (2) CN102803261A (es)
AR (2) AR079905A1 (es)
AU (2) AU2011206635B2 (es)
BR (2) BR112012017442A2 (es)
CA (2) CA2784769A1 (es)
CL (2) CL2012001956A1 (es)
EA (2) EA022093B1 (es)
ES (2) ES2523977T3 (es)
IL (2) IL220838A0 (es)
MX (2) MX2012008259A (es)
NZ (2) NZ600648A (es)
PE (2) PE20121512A1 (es)
PH (2) PH12012501381A1 (es)
SG (2) SG182505A1 (es)
TW (2) TWI473807B (es)
WO (2) WO2011086099A1 (es)
ZA (2) ZA201205240B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
CA2755467A1 (en) 2009-05-07 2010-12-23 Janssen Pharmaceuticals, Inc. Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
NZ597140A (en) * 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
AU2011206635B2 (en) 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AU2011295440B2 (en) 2010-08-27 2015-06-11 Merck Patent Gmbh Triazolopyrazine derivatives
EP2611805A1 (en) 2010-09-02 2013-07-10 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
ES2674451T3 (es) * 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
JP6049768B2 (ja) * 2012-03-07 2016-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung トリアゾロピラジン誘導体
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリダジン
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
CN103508957B (zh) * 2012-06-25 2017-02-08 中国科学院上海药物研究所 羟乙基吡唑类化合物或氨乙基吡唑类化合物及其制备方法和用途
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
EP2687528A1 (en) 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
CN107266405A (zh) * 2012-08-07 2017-10-20 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
DK3004080T3 (da) * 2013-06-04 2019-01-02 Acturum Real Estate Ab Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer
WO2014195323A1 (en) 2013-06-04 2014-12-11 Acturum Life Science AB Pyrimidine compounds and their use as gamma secretase modulators
US9611254B2 (en) 2013-06-04 2017-04-04 Acturum Life Science AB Triazole compounds and their use as gamma secretase modulators
PE20160156A1 (es) 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
WO2016090371A2 (en) 2014-12-05 2016-06-09 An2H Discovery Limited Parkin ligase activation methods and compositions
KR101594470B1 (ko) 2015-05-28 2016-02-16 주식회사 네비엔 프리캐스트 콘크리트 슬래브 및 이들의 결합구조
KR101710943B1 (ko) 2016-05-13 2017-02-28 강태성 구조물용 피씨 데크 슬래브 및 이의 제조방법
US10308617B2 (en) 2016-06-03 2019-06-04 An2H Discovery Limited Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
JP7012715B2 (ja) * 2016-06-27 2022-01-28 エフ.ホフマン-ラ ロシュ アーゲー γ-セクレターゼモジュレーターとしてのトリアゾロピリジン
EP3481829B1 (en) 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Fused pyrimidine derivatives
CN109476670B (zh) * 2016-10-04 2022-06-28 豪夫迈·罗氏有限公司 二环杂芳基衍生物
CN109790149B (zh) * 2016-11-08 2022-05-17 豪夫迈·罗氏有限公司 苯氧基三唑类化合物
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CN110194743B (zh) * 2018-02-26 2022-11-11 云南大学 苯基(3-甲氧基-4-(4-甲基-1h-咪唑-1-基)苯基)甲酮类化合物
CN110194744B (zh) * 2018-02-26 2022-11-11 云南大学 一种抑制β-淀粉样蛋白生成的化合物及其制备方法和用途
CN110194746B (zh) * 2018-02-26 2022-11-18 云南大学 用于治疗阿尔茨海默症的化合物,其制备方法和用途
WO2021105337A1 (en) 2019-11-29 2021-06-03 F. Hoffmann-La Roche Ag Process for the preparation (9s)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepine
WO2022122864A1 (en) 2020-12-11 2022-06-16 F. Hoffmann-La Roche Ag Process for the preparation of (9s)-n-[3-(6-methylpyrimidin-4-yl)-3-azabicyclo[3.2.1]octan-8-yl]-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[1,5-a]azepin-2-amine and its solid form

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
DE69615376T2 (de) 1995-07-13 2002-09-05 Knoll Gmbh Piperazin-derivate als heilmittel
YU86801A (sh) 1999-06-10 2004-07-15 Warner-Lambert Company Izoindol derivati korisni u inhibiciji agregacije amiloidnih proteina i snimanju amiloidnih naslaga
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
CA2516634A1 (en) 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag Ccr-3 receptor antagonists
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
DE602004025354D1 (de) 2003-08-14 2010-03-18 Hoffmann La Roche Gabanerge modulatoren
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
MX2007011234A (es) 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006293635A1 (en) 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as CCR3 receptor liquids
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
CN101283031B (zh) 2005-10-11 2012-10-10 科聚亚公司 二芳基胺
CA2628455A1 (en) 2005-11-10 2007-05-24 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
PL1992618T3 (pl) * 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US7951818B2 (en) 2006-12-01 2011-05-31 Galapagos Nv Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
KR20090090364A (ko) 2006-12-12 2009-08-25 쉐링 코포레이션 트리사이클릭 환 시스템을 함유하는 아스파르틸 프로테아제 억제제
WO2008082490A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
CA2686589A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
AU2008250436B2 (en) 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
EP2178857A1 (en) 2007-06-29 2010-04-28 Schering Corporation Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ES2529648T3 (es) * 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
JP2010538068A (ja) 2007-09-06 2010-12-09 シェーリング コーポレイション ガンマセクレターゼモジュレーター
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
US8426595B2 (en) 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators
AU2009216851B2 (en) * 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
KR20110033223A (ko) 2008-06-20 2011-03-30 제넨테크, 인크. 트리아졸로피리딘 jak 억제제 화합물 및 방법
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
CA2742317A1 (en) 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
AU2009312856A1 (en) * 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
WO2010065310A1 (en) 2008-12-03 2010-06-10 Via Pharmaceuticals, Inc Inhibitors of diacylglycerol acyltransferase
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP2012519682A (ja) 2009-03-03 2012-08-30 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規フェニルイミダゾールおよびフェニルトリアゾール
EP2410529A1 (en) 2009-03-16 2012-01-25 Panasonic Corporation Application running device
CN102414210A (zh) 2009-04-27 2012-04-11 高点制药有限责任公司 作为β-分泌酶抑制剂的取代的咪唑并[1,2-a]吡啶衍生物、药物组合物和使用方法
CA2755467A1 (en) 2009-05-07 2010-12-23 Janssen Pharmaceuticals, Inc. Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
AU2011206635B2 (en) 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
AU2012230348A1 (en) 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa

Also Published As

Publication number Publication date
IL220838A0 (en) 2012-08-30
EA021776B1 (ru) 2015-08-31
TWI473807B (zh) 2015-02-21
PH12012501381A1 (en) 2012-10-22
CA2784765A1 (en) 2011-07-21
TW201134824A (en) 2011-10-16
PH12012501382A1 (en) 2012-10-22
SG182505A1 (en) 2012-08-30
EA022093B1 (ru) 2015-10-30
CA2784769A1 (en) 2011-07-21
MX2012008259A (es) 2012-08-17
AU2011206634B2 (en) 2014-11-13
AR079905A1 (es) 2012-02-29
EP2523949B1 (en) 2014-08-20
EP2523955B1 (en) 2014-07-16
AU2011206634A1 (en) 2012-07-19
BR112012017310A2 (pt) 2016-04-19
MX2012008260A (es) 2012-08-17
CN102803261A (zh) 2012-11-28
WO2011086098A1 (en) 2011-07-21
IL220840A (en) 2014-03-31
EA201290654A1 (ru) 2012-12-28
ES2523977T3 (es) 2014-12-03
JP5824464B2 (ja) 2015-11-25
KR20130028048A (ko) 2013-03-18
CL2012001956A1 (es) 2013-01-25
TWI491608B (zh) 2015-07-11
KR20120123677A (ko) 2012-11-09
CN102906083A (zh) 2013-01-30
AR079904A1 (es) 2012-02-29
NZ601150A (en) 2014-06-27
AU2011206635A1 (en) 2012-07-05
ZA201205245B (en) 2014-12-23
PE20121511A1 (es) 2012-12-06
US9145399B2 (en) 2015-09-29
ZA201205240B (en) 2015-02-25
TW201136918A (en) 2011-11-01
SG182506A1 (en) 2012-08-30
JP2013517247A (ja) 2013-05-16
EP2523949A1 (en) 2012-11-21
CL2012001955A1 (es) 2012-11-30
NZ600648A (en) 2014-06-27
US9079886B2 (en) 2015-07-14
WO2011086099A1 (en) 2011-07-21
ES2512840T3 (es) 2014-10-24
EP2523955A1 (en) 2012-11-21
AU2011206635B2 (en) 2015-01-22
US20120295891A1 (en) 2012-11-22
EA201290655A1 (ru) 2012-12-28
JP2013517246A (ja) 2013-05-16
BR112012017442A2 (pt) 2016-04-19
US20120295901A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
PE20051051A1 (es) Compuestos de triazol como antagonistas de la vasopresina
PE20142258A1 (es) Compuesto heterociclico nitrogenado
TW200637828A (en) Novel cis-imidazolines
PE20091095A1 (es) Moduladores de gamma secretasa
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
EA201270166A1 (ru) Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
NZ599343A (en) Substituted piperidines that increase p53 activity and the uses thereof
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
SMT201300096B (it) Inibitori di prolil idrossilasi
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
EA201171008A1 (ru) Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
MY154668A (en) 5-membered heterocyclic amides and related compounds
JO3070B1 (ar) عوامل لمعالجة إضطرابات تتضمن تعديل مستقبلات الريانودين
EA201290654A1 (ru) Новые замещенные триазольные производные как модуляторы гамма-секретазы
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2010004501A (es) Inhibidor de la proteina de activacion de 5-lipoxigenasa (plap).
CO6241118A2 (es) Formas amorfas estabilizadas de mesilato de imatinib
SV2005002099A (es) &#34; nuevos compuestos &#34; ref. pc 32096a
MX2014005075A (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
TN2012000132A1 (en) N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1

Legal Events

Date Code Title Description
FD Application declared void or lapsed